RxDoctor Payments Data

Edward Koo, MD

Ophthalmology · Burlingame, CANPI 1649376823

Payments from drug & device makers

$27,149in general payments, 2019–2025

Across 58 payments — averaging $468.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec Cataract Technology Inc.$16K
  • Carl Zeiss Meditec, Inc.$9K
  • Alcon$910
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$321
  • Carl Zeiss Meditec USA, Inc.$204
  • Biotissue Holdings Inc.$160
  • plus $364 from 11 others

What the payments were for

  • Consulting fees$24,20089%
  • Travel & lodging$5382%
  • Food & beverage$2,3929%
  • Gifts$190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,149 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$528,758
Medicare patients
813
Services billed
5,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast28$23,205
LumiganBimatoprost38$17,279
Travoprost50$10,920
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol53$9,219
Cyclosporine15$7,959
SimbrinzaBrinzolamide/Brimonidine Tart17$5,227
Latanoprost365$4,810
Timolol Maleate107$3,532
Prednisolone Acetate73$2,162
Brinzolamide14$1,797
Ketorolac Tromethamine57$1,165
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat52$1,152
Ofloxacin47$464
Doxycycline Monohydrate12$418
Brimonidine Tartrate26$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$21$23,20528 claims
AbbVieLumigan$68$17,27938 claims
AlconSimbrinza$910$5,22717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Burlingame

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →